Wee1 Inhibitor I
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H562590

CAS#: 622855-37-2

Description: Wee1 Inhibitor I is an ATP-binding site-targeting inhibitor of Wee1.

Chemical Structure

img
Wee1 Inhibitor I
CAS# 622855-37-2
Instruction

Theoretical Analysis

Hodoodo Cat#: H562590
Name: Wee1 Inhibitor I
CAS#: 622855-37-2
Chemical Formula: C20H11ClN2O3
Exact Mass: 362.05
Molecular Weight: 362.760
Elemental Analysis: C, 66.22; H, 3.06; Cl, 9.77; N, 7.72; O, 13.23

Price and Availability

Size Price Availability Quantity
1mg USD 350
Bulk inquiry

Synonym: Wee1 Inhibitor I; Wee1-Inhibitor I; Wee1-Inhibitor-I; Wee1 Inhibitor-I;

IUPAC/Chemical Name: 4-(2-Chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3-(2H,6H)-dione

InChi Key: DPEXRCOBPACFOO-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H11ClN2O3/c21-13-4-2-1-3-10(13)11-8-15-16(18-17(11)19(25)23-20(18)26)12-7-9(24)5-6-14(12)22-15/h1-8,22,24H,(H,23,25,26)

SMILES Code: O=C1NC(C2=C1C3=C(C=C2C4=CC=CC=C4Cl)NC5=C3C=C(O)C=C5)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 362.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schmidt M, Rohe A, Platzer C, Najjar A, Erdmann F, Sippl W. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules. 2017 Nov 23;22(12). pii: E2045. doi: 10.3390/molecules22122045. Review. PubMed PMID: 29168755.

2: Mills CC, Kolb EA, Sampson VB. Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer. Cancer Res. 2017 Dec 1;77(23):6489-6498. doi: 10.1158/0008-5472.CAN-17-2066. Epub 2017 Nov 2. Review. PubMed PMID: 29097609; PubMed Central PMCID: PMC5712276.

3: Brandsma I, Fleuren EDG, Williamson CT, Lord CJ. Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14. Review. PubMed PMID: 28984489.

4: Visconti R, Grieco D. Fighting tubulin-targeting anticancer drug toxicity and resistance. Endocr Relat Cancer. 2017 Sep;24(9):T107-T117. doi: 10.1530/ERC-17-0120. Review. PubMed PMID: 28808045.

5: Abou Zahr A, Borthakur G. Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opin Emerg Drugs. 2017 Jun;22(2):137-148. doi: 10.1080/14728214.2017.1330885. Epub 2017 May 22. Review. PubMed PMID: 28506135.

6: Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016 Oct;37(10):872-881. doi: 10.1016/j.tips.2016.06.006. Epub 2016 Jul 14. Review. PubMed PMID: 27427153.

7: Tamura K. Development of cell-cycle checkpoint therapy for solid tumors. Jpn J Clin Oncol. 2015 Dec;45(12):1097-102. doi: 10.1093/jjco/hyv131. Epub 2015 Oct 20. Review. PubMed PMID: 26486823.

8: Benada J, Macurek L. Targeting the Checkpoint to Kill Cancer Cells. Biomolecules. 2015 Aug 18;5(3):1912-37. doi: 10.3390/biom5031912. Review. PubMed PMID: 26295265; PubMed Central PMCID: PMC4598780.

9: Karantanos T, Theodoropoulos G, Pektasides D, Gazouli M. Clock genes: their role in colorectal cancer. World J Gastroenterol. 2014 Feb 28;20(8):1986-92. doi: 10.3748/wjg.v20.i8.1986. Review. PubMed PMID: 24587674; PubMed Central PMCID: PMC3934468.

10: Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013 Oct 1;12(19):3159-64. doi: 10.4161/cc.26062. Epub 2013 Aug 26. Review. PubMed PMID: 24013427; PubMed Central PMCID: PMC3865011.

11: Yanagida M, Ikai N, Shimanuki M, Sajiki K. Nutrient limitations alter cell division control and chromosome segregation through growth-related kinases and phosphatases. Philos Trans R Soc Lond B Biol Sci. 2011 Dec 27;366(1584):3508-20. doi: 10.1098/rstb.2011.0124. Review. PubMed PMID: 22084378; PubMed Central PMCID: PMC3203466.

12: Madoux F, Mishra J, Mercer BA, Ayad N, Roush W, Hodder P, Rosen HR. Small Molecule Inhibitors of Wee1 Degradation and Mitotic Entry. 2009 Aug 14 [updated 2011 Mar 25]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK56226/ PubMed PMID: 21735595.

13: Chevalier C, Nafati M, Mathieu-Rivet E, Bourdon M, Frangne N, Cheniclet C, Renaudin JP, Gévaudant F, Hernould M. Elucidating the functional role of endoreduplication in tomato fruit development. Ann Bot. 2011 May;107(7):1159-69. doi: 10.1093/aob/mcq257. Epub 2011 Jan 3. Review. PubMed PMID: 21199834; PubMed Central PMCID: PMC3091799.

14: Stathis A, Oza A. Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect. 2010 Sep;23(7):425-9. doi: 10.1358/dnp.2010.23.7.1490760. Review. PubMed PMID: 20862394.

15: Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol. 2010 Aug;5(3):186-91. Review. PubMed PMID: 20406171.

16: Francis D. The G2/M transition in eukaryotes. SEB Exp Biol Ser. 2008;59:81-98. Review. PubMed PMID: 18368919.

17: Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci. 2001 Nov;58(12-13):1907-22. Review. PubMed PMID: 11766887.

18: Maller JL, Gross SD, Schwab MS, Finkielstein CV, Taieb FE, Qian YW. Cell cycle transitions in early Xenopus development. Novartis Found Symp. 2001;237:58-73; discussion 73-8. Review. PubMed PMID: 11444050.